FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2745305087> ?p ?o ?g. }

• W2745305087 endingPage "3170" @default.
• W2745305087 startingPage "3170" @default.
• W2745305087 abstract "Abstract Introduction: DAC is a hypomethylating agent FDA approved for the treatment of advanced myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML).Despite its clinical activity, the duration of response is limited and prognosis at relapse is poor. In pre-clinical studies, we identified potent epigenetic effects of ATO alone and in combination with DAC, and also found that carboplatin (Carbo) can enhance gene reactivation in combination with DAC. We therefore initiated a randomized phase 2 clinical trial (NCT02188706) to compare the safety and efficacy of DAC in combination with either Carbo or ATO as compared to single agent DAC in patients with MDS/CMML and Acute Myeloid Leukemia. Here we present updated results for the MDS/CMML cohort. Methods: Patients with MDS/CMML INT-1 were randomized to one of three regimens: DAC 20 mg/m2 days 1-5, (DAC), DAC as above and Carbo AUC 5 on day 8 (DAC/Carbo), or DAC as above and ATO 0.15 mg/kg days 1-5 (DAC/ATO). We used adaptive randomization based on response rate which started after 10 patients were equally randomized to each arm. Cycles were scheduled every 28 days for a minimum of 4 cycles. Dose reductions/delays were allowed based on response and tolerability. Patients remained on treatment as long as they continued to benefit without toxicity. The primary endpoint was the composite response rate: the complete response (CR: complete response, mCR: marrow complete response and CRi: complete response with incomplete blood count recovery) and partial response (PR) rates using the modified IWG 2006 criteria. Secondary endpoints included median overall survival (OS) and safety. DNA methylation changes were measured using LINE1 bisulfite/pyrosequencing. Results: As of July 2016, 42 patients (MDS = 40, CMML=2) have been enrolled on study. Median age was 71 years (range, 35 to 84 years). There was no statistically significant difference in patients' characteristics between the three arms. Median number of cycles for the treatment arms was 4 (range, 1-15). Response data was evaluable for 36 patients (8 on DAC alone, 5 on DAC/Carbo and 23 on DAC/ATO). Composite responses were seen in 3/8 patients on DAC (37.5%), 0/5 patients on DAC/Carbo (0%, p=0.23 compared to DAC alone) and 12/23 patients on DAC/ATO (52.2%, p=0.69 compared to DAC alone). Median OS among MDS/CMML patients receiving DAC/ATO (17.8 months) was improved compared to the DAC/Carbo (3.9 months) and DAC (9.8 months) arms (p=0.01) [Figure 1]. There was not a significant difference in high-grade (≥ grade 3) toxicity between the three arms, with grade 3 neutropenia and thrombocytopenia as the most common side effects. DNA methylation analysis showed equivalent demethylation in all the arms, suggesting that the epigenetic effects of ATO were independent of DNA methylation, which was consistent with pre-clinical studies. Conclusion: Our results demonstrate higher response rates and a significant survival benefit with the combination of DAC and ATO in comparison to DAC alone in patients with MDS/CMML. Disclosures Kropf: Celgene: Consultancy; Takeda: Consultancy. Fung:Amgen: Consultancy; Genzyme: Consultancy. Kantarjian:ARIAD: Research Funding; Bristol-Myers Squibb: Research Funding; Amgen: Research Funding; Pfizer Inc: Research Funding; Delta-Fly Pharma: Research Funding; Novartis: Research Funding. Issa:Astex Pharmaceuticals: Consultancy; Teva Pharmaceutical Industries: Consultancy." @default.
• W2745305087 created "2017-08-17" @default.
• W2745305087 creator A5039625388 @default.
• W2745305087 creator A5057822243 @default.
• W2745305087 creator A5062330946 @default.
• W2745305087 creator A5064201088 @default.
• W2745305087 creator A5067227071 @default.
• W2745305087 creator A5075930791 @default.
• W2745305087 creator A5078169970 @default.
• W2745305087 creator A5079853830 @default.
• W2745305087 creator A5090435894 @default.
• W2745305087 date "2016-12-02" @default.
• W2745305087 modified "2023-09-28" @default.
• W2745305087 title "Improved Survival for MDS/CMML Patients Treated with the Combination of Decitabine (DAC) and Arsenic Trioxide (ATO) in a Phase II Adaptive Three Arm Randomization Study: DAC Alone Vs. DAC +/- Carboplatin or ATO" @default.
• W2745305087 doi "https://doi.org/10.1182/blood.v128.22.3170.3170" @default.
• W2745305087 hasPublicationYear "2016" @default.
• W2745305087 type Work @default.
• W2745305087 sameAs 2745305087 @default.
• W2745305087 citedByCount "0" @default.
• W2745305087 crossrefType "journal-article" @default.
• W2745305087 hasAuthorship W2745305087A5039625388 @default.
• W2745305087 hasAuthorship W2745305087A5057822243 @default.
• W2745305087 hasAuthorship W2745305087A5062330946 @default.
• W2745305087 hasAuthorship W2745305087A5064201088 @default.
• W2745305087 hasAuthorship W2745305087A5067227071 @default.
• W2745305087 hasAuthorship W2745305087A5075930791 @default.
• W2745305087 hasAuthorship W2745305087A5078169970 @default.
• W2745305087 hasAuthorship W2745305087A5079853830 @default.
• W2745305087 hasAuthorship W2745305087A5090435894 @default.
• W2745305087 hasConcept C104317684 @default.
• W2745305087 hasConcept C126322002 @default.
• W2745305087 hasConcept C143998085 @default.
• W2745305087 hasConcept C150194340 @default.
• W2745305087 hasConcept C168563851 @default.
• W2745305087 hasConcept C190727270 @default.
• W2745305087 hasConcept C197934379 @default.
• W2745305087 hasConcept C203092338 @default.
• W2745305087 hasConcept C2776012956 @default.
• W2745305087 hasConcept C2776063141 @default.
• W2745305087 hasConcept C2776239401 @default.
• W2745305087 hasConcept C2776364478 @default.
• W2745305087 hasConcept C2776694085 @default.
• W2745305087 hasConcept C2777928532 @default.
• W2745305087 hasConcept C2778239845 @default.
• W2745305087 hasConcept C2778375690 @default.
• W2745305087 hasConcept C2780007613 @default.
• W2745305087 hasConcept C2780235182 @default.
• W2745305087 hasConcept C2780817109 @default.
• W2745305087 hasConcept C2781451048 @default.
• W2745305087 hasConcept C31760486 @default.
• W2745305087 hasConcept C535046627 @default.
• W2745305087 hasConcept C55493867 @default.
• W2745305087 hasConcept C71924100 @default.
• W2745305087 hasConcept C86803240 @default.
• W2745305087 hasConceptScore W2745305087C104317684 @default.
• W2745305087 hasConceptScore W2745305087C126322002 @default.
• W2745305087 hasConceptScore W2745305087C143998085 @default.
• W2745305087 hasConceptScore W2745305087C150194340 @default.
• W2745305087 hasConceptScore W2745305087C168563851 @default.
• W2745305087 hasConceptScore W2745305087C190727270 @default.
• W2745305087 hasConceptScore W2745305087C197934379 @default.
• W2745305087 hasConceptScore W2745305087C203092338 @default.
• W2745305087 hasConceptScore W2745305087C2776012956 @default.
• W2745305087 hasConceptScore W2745305087C2776063141 @default.
• W2745305087 hasConceptScore W2745305087C2776239401 @default.
• W2745305087 hasConceptScore W2745305087C2776364478 @default.
• W2745305087 hasConceptScore W2745305087C2776694085 @default.
• W2745305087 hasConceptScore W2745305087C2777928532 @default.
• W2745305087 hasConceptScore W2745305087C2778239845 @default.
• W2745305087 hasConceptScore W2745305087C2778375690 @default.
• W2745305087 hasConceptScore W2745305087C2780007613 @default.
• W2745305087 hasConceptScore W2745305087C2780235182 @default.
• W2745305087 hasConceptScore W2745305087C2780817109 @default.
• W2745305087 hasConceptScore W2745305087C2781451048 @default.
• W2745305087 hasConceptScore W2745305087C31760486 @default.
• W2745305087 hasConceptScore W2745305087C535046627 @default.
• W2745305087 hasConceptScore W2745305087C55493867 @default.
• W2745305087 hasConceptScore W2745305087C71924100 @default.
• W2745305087 hasConceptScore W2745305087C86803240 @default.
• W2745305087 hasIssue "22" @default.
• W2745305087 hasLocation W27453050871 @default.
• W2745305087 hasOpenAccess W2745305087 @default.
• W2745305087 hasPrimaryLocation W27453050871 @default.
• W2745305087 hasRelatedWork W2042704711 @default.
• W2745305087 hasRelatedWork W2262636126 @default.
• W2745305087 hasRelatedWork W2555024572 @default.
• W2745305087 hasRelatedWork W2563465935 @default.
• W2745305087 hasRelatedWork W2907613272 @default.
• W2745305087 hasRelatedWork W2970304739 @default.
• W2745305087 hasRelatedWork W2980310053 @default.
• W2745305087 hasRelatedWork W4206174687 @default.
• W2745305087 hasRelatedWork W4295851473 @default.
• W2745305087 hasRelatedWork W4310093714 @default.
• W2745305087 hasVolume "128" @default.
• W2745305087 isParatext "false" @default.
• W2745305087 isRetracted "false" @default.
• W2745305087 magId "2745305087" @default.
• W2745305087 workType "article" @default.